OPTUS Pharmaceutical Co., Ltd. Logo

OPTUS Pharmaceutical Co., Ltd.

Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.

131030 | KO

Overview

Corporate Details

ISIN(s):
KR7131030009
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 오송생명6로 50, 청주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

OPTUS Pharmaceutical Co., Ltd. (formerly DHP Korea Co Ltd) is a specialized pharmaceutical company dedicated to providing total eye care solutions. The company develops, manufactures, and markets a comprehensive portfolio of ophthalmic products targeting conditions such as dry eye syndrome, bacterial infections, and inflammation. Its product line includes preservative-free artificial tears and medicated eye drops with active ingredients like sodium hyaluronate, cyclosporine, and moxifloxacin. OPTUS Pharmaceutical operates a dedicated, GMP-compliant manufacturing plant that specializes in producing single-dose ophthalmic preparations, ensuring high standards of safety and quality. The company is committed to continuous research and innovation in eye health and also provides contract manufacturing services.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 994.7 KB
2025-07-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 898.2 KB
2025-04-15 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.0 KB
2025-04-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 30.2 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 33.7 KB
2025-03-25 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 18.4 KB
2025-03-25 00:00
Board/Management Information
대표이사변경
Korean 9.1 KB
2025-03-17 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.1 MB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 17.6 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 135.1 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 126.7 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 19.1 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 120.2 KB
2025-03-07 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 111.4 KB

Automate Your Workflow. Get a real-time feed of all OPTUS Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OPTUS Pharmaceutical Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OPTUS Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM

Talk to a Data Expert

Have a question? We'll get back to you promptly.